about
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast CancerDiagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation.Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.Treating cancer with selective CDK4/6 inhibitors.Mismatch repair as a prognostic marker for adjuvant therapy in colorectal cancer - how soon is now?Recalibrating emergency care in the UK: pulling our weight.Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.Converting Inoperable Colorectal Liver Metastases to Operable; Data from a UK Perspective.The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trialUltra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencingmutations in metastatic lobular breast cancer patientsAnother patient with low back painRadiotherapy-associated Pemphigus - a Rare Cause of Grade 4 Skin ToxicityScience in Focus: Circulating Tumour DNA as a Liquid BiopsyUK Training in Clinical Oncology: The Trainees' ViewpointComparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA AnalysisInactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceCirculating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer
P50
Q33429765-95713F3D-8D4E-4310-9166-79FD5112CF52Q36168078-A1F06D00-F588-4E20-AC55-CEC600ECE551Q37704012-46C0E1AD-83FB-4C93-9F0D-4191CE4AF240Q38379925-FB04FDF4-3FBC-4731-BFFC-B338DFE8C22CQ38794109-21CCCF08-9AF8-4E54-8179-0C28FE07912EQ44834334-B97A7A37-657D-4C76-BD03-6D9F9BADBBCEQ47389194-6B92DC8B-23E3-49F3-8286-2962856BA6C6Q48523669-A427C3FC-146C-4802-BCD4-AAC1BFBB8641Q52645860-C86E167B-8AB4-4E2D-9DDF-0A4AC84F9C4BQ52678229-47B95EBD-98F5-4B0A-98CE-64AD7BF05B5BQ53606810-DD7F6582-4651-4787-B39E-D88BD951026FQ57158292-9C19EEA6-1847-4026-AC86-B40051B3251DQ58699975-91E46A92-2E09-46C1-B16A-5D99C3710E1EQ64114099-E2C455E7-9B92-4080-8A08-BDBBE5273260Q84382829-DB07C918-CBF0-41E2-91A1-EEE7E99699CCQ88314304-B73DB979-2DDD-4490-8A3B-FA461EFCAB03Q88511691-E62DD9BC-7A85-4BAC-B4B5-94286A288742Q89460981-0F1B9731-5C41-468D-9AF8-1FFFD6275F56Q90260923-B3BB73E0-0E8A-4F50-87E7-C43EAF6E6EBCQ90573451-34B73715-E0A6-4899-BCD4-7E1DC3EDF794Q91728893-FC7CD343-AF4B-46B8-9DAD-9A46EDBB380B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ben O'Leary
@ast
Ben O'Leary
@en
Ben O'Leary
@es
Ben O'Leary
@sl
type
label
Ben O'Leary
@ast
Ben O'Leary
@en
Ben O'Leary
@es
Ben O'Leary
@sl
prefLabel
Ben O'Leary
@ast
Ben O'Leary
@en
Ben O'Leary
@es
Ben O'Leary
@sl
P106
P21
P31
P496
0000-0002-1092-9169